Hengrui Therapeutics, Inc. (HTI), located in Princeton, NJ, is a biotech focused on early-stage clinical development of innovative therapeutics in areas of major unmet medical needs, such as oncology, metabolic and autoimmune disorders.
HTI's pipeline consists of multiple clinical-stage assets that have first-in-class or best-in-class potentials, including targeted oncology therapies, antibody-drug conjugates, and immune-modulating antibodies.
